Clinical Trial Search

Primary: Model Predicted Baseline-corrected and Placebo-corrected QT Interval Corrected for Heart Rate (HR) Using Fridericia's Formula (QTcF)(ΔΔQTcF) (Derived From…

Primary: Change in Peak Expiratory Flow (Absolute Value) — 175; 160 ml/min — p=0.374

Primary: Pharmacokinetics Parameter — 17.39; 16.20; 103.69; 93.61 pg/mL

Primary: Area Under the Concentration-time Curve From Time Zero (Pre-dose) Extrapolated to Infinite Time (AUC[0-inf]) in Plasma Following Administration of Oral Dose of…

Primary: Frequency of Handwashing — 412; 432; 65; 75 Participants

Primary: The Changes in HbA1c at Week 24 — -0.72; -0.01 percentage of HbA1c

Primary: Incidence of Clinical Episodes of Malaria — 304.8; 278.2; 113.3 No. of events/1000 person years at risk

Primary: Percentage of Participants Who Complete All 6 Sessions — 78.9 percentage of participants

Primary: Maximum Tolerated Dose of Bortezomib (Phase I) — 1.3 mg/m^2

Primary: Percentage of Participants With Objective Response — 0; 0; 0 percentage of participants

Primary: Platelet Reactivity Measured by Vasodilator Stimulated Phosphoprotein (VASP) Platelet Reactivity Index (PRI %) — 25; 32; 31; 38 PRI% — p=0.105

Primary: Number of Participants With Local and Systemic Adverse Events in Year 1 — 2; 6; 4; 6 Participants

Primary: Change in HbA1c From Baseline to Week 24 — -0.95; -0.14 percentage of HbA1c

Primary: Treatment Entry: IP Treatment Status — 10; 8; 6 count of participants — p=0.02578184

Primary: Pre-treatment Serum Level of Endogenous Anti-TNF in Relation to Primary Clinical Response or Non-response — NA endogenous anti-TNF serum level (µg/mL)